A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial)
Authors
Besse, B.Paz-Ares, L. G.
Peters, S.
Cappuzzo, F.
Reck, M.
Calles, A.
Califano, Raffaele
Lopez-Vilarino, J. A.
Veramendi, S.
Kahatt, C. M.
Zeaiter, A. H.
Sands, J.
Affiliation
Institut Gustave Roussy, Villejuif, FranceIssue Date
2023
Metadata
Show full item recordCitation
Besse B, Paz-Ares LG, Peters S, Cappuzzo F, Reck M, Calles A, et al. A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005484.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.TPS8613Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS8613Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.TPS8613